Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
|Slideshows|April 11, 2019
This Month's Top Stories from Endocrinology Network
Are blood sugar levels moving targets? Should pregnant women be screened for thyroid cancer? And, will there soon be treatment to stave off those salt and sugar cravings? Learn more about these and other developments from endocrinology research in this news recap.
Advertisement
Are blood sugar levels moving targets? Should pregnant women be screened for thyroid cancer? And, will there soon be treatment to stave off those salt and sugar cravings? Learn more about these and other developments from endocrinology research in this news recap.
Advertisement
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease
3
When Innovation Builds Clinical Confidence: Evaluating Treatment Options in Hemophilia A
4
The HCPFive: Top News for Healthcare Providers from the Week of 09/13
5